Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera Post author:Sam Post published:January 25, 2018 Post category:BioPharma The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace You Might Also Like Parexel International Taps New CEO Jamie Macdonald March 5, 2018 This Tiny Massachusetts Biotech Could Reap Big Rewards for Investors October 26, 2017 Astellas Takes Out Belgium Biotech in Deal Worth $853 Million April 2, 2017
